- Login
- Register
- Home/Current Issue
- About the journal
- Editorial board
- Online submission
- Instructions for authors
- Subscriptions
- Foundation Acta Endocrinologica
- Archive
- Contact
Romanian Academy
The Publishing House of the Romanian Academy
ACTA ENDOCRINOLOGICA (BUC)
The International Journal of Romanian Society of Endocrinology / Registered in 1938in Web of Science Master Journal List
Acta Endocrinologica(Bucharest) is live in PubMed Central
Journal Impact Factor - click here.
-
General Endocrinology
Malutan A, Drugan T, Georgescu C, Ciortea R, Bucuri C, Bobric A, Rada MP, Mihu D
Vascular Endothelial Growth Factor Serum Levels in Women with Advanced EndometriosisActa Endo (Buc) 2016 12(1): 7-13 doi: 10.4183/aeb.2016.7
AbstractContext. Endometriosis is a common gynecological disease, characterized by ectopic deposits of endometrial tissue outside of the uterine cavity, and it is associated with pelvic pain and infertility, with an important impact on the quality of life. At this point there is a controversy regarding the etiology and pathophysiology of endometriosis and it seems that pro-angiogenic growth factors might be involved, but their role is not completely understood. Objective. To evaluate the serum concentration of the main growth factors in patients with diagnosed endometriosis compared to healthy controls. S ubjects and Methods. A total of 157 women were divided into two study groups (Group I – endometriosis; Group 2 – healthy women). Serum levels of VEGF, G-CSF, GM-CSF, b-FGF, EGF, and HGF were measured with Human Multiplex Cytokine Panels. Results. VEGF serum levels were significantly lower in women with endometriosis compared to controls (1.924±0.145 compared to 1.806±0.078 pg/mL, p<0.001). Serum levels of GM-CSF, b-FGF, EGF, and HGF respectively did not differ significantly between patients with endometriosis and healthy controls. G-CSF had a very low detection rate. Conclusions. The present study showed that VEGF serum levels are significantly lower in endometriosis patients compared to healthy controls, indicating a possible role in endometriosis pathogenesis. -
General Endocrinology
Malutan AM, Costin N, Ciortea R, Dragos C.M, Mihu D, Dorin G
Bone Mineral Density and Proinflamatory Cytokines (IL-1ß and TNFa) in MenopauseActa Endo (Buc) 2014 10(2): 169-180 doi: 10.4183/aeb.2014.169
AbstractBackground. Osteoporosis has a high incidence after menopause, and at the same time the relationship between menopausal oestrogen deprivation and proinflammatory status is considered to be involved in postmenopausal bone turnover. Objective. The aim of this study was to evaluate the serum levels of IL-1β and of the TNFα in pre and postmenopausal women, as well as to investigate the relationship between these cytokines and bone mineral density. Design. A case-control study was performed during a period of 12 months. Subjects and Methods. The study included 150 women divided into 4 study groups. Serum levels of IL-1β and TNFα were determined using multiplex cytokine kits. BMD was measured by DXA at the level of the hip and lumbar spine. Results. Serum concentration of IL-1β is significantly higher in natural and surgically induced menopausal women, compared to women in the control group. Serum levels of TNFα in postmenopausal women and with surgically induced menopause are significantly higher than in fertile and premenopausal women. Serum levels of IL-1β are significantly higher in patients with osteopenia and osteoporosis compared to patients with normal BMD values. We found a negative correlation between serum levels of IL-1β, TNFα and BMD in pre and postmenopausal women, and in women with surgically induced menopause. Conclusions. Serum levels of IL- 1β and TNFα are significantly higher in menopausal women compared to fertile women. IL-1β is significantly higher in patients with osteopenia and osteoporosis than in women with normal BMD values, and IL-1β and TNFα associate negatively with BMD in pre and postmenopausal women, as well as in women with surgically induced menopause. -
General Endocrinology
Ciortea R
Additive effect of melatonin to estradiol upon visceral fat mass in ovariectomized ratsActa Endo (Buc) 2010 6(3): 315-326 doi: 10.4183/aeb.2010.315
AbstractBackground. Intraabdominal obesity is considered a low level chronic proinflammatory state. The adipocyte is the central element that integrates multiple metabolic and endocrine signals.\r\nObjectives. This study monitors the metabolic effects of the administration of melatonin or melatonin associated with estrogen in surgically castrated female rats.\r\nMaterial and method. Experiments were performed in white female Wistar rats, with a weight of 160-200 g. At 14 days postovariectomy, a time period required for the postoperative validation of ovarian failure, with the experimental induction of artificial\r\nmenopause in the studied animals, estrogen replacement treatment and combined treatment of estrogen and melatonin were initiated. The duration of the administered treatment, with the products and the doses recommended for veterinary use, was of 12 consecutive weeks.\r\nResults. Food consumption (p=0.60), glycemia (p=0.053) and TG (p=0.34) did not significantly differ between the groups. The comparison of weight and intra-retroperitoneal\r\nfat between the groups in the last week showed that groups which did not receive estrogen had a significantly higher weight and higher intra-retroperitoneal fat than groups to which estrogen was administered (p<0.001). Groups which received estrogen associated with melatonin had a lower weight and a lower intra-retroperitoneal fat compared to groups, which received estrogen alone (p<0.001). Melatonin administred alone (without estrogens)does not show any effects on weight or lipid metabolism in ovarectomised rats.\r\nConclusion. In ovarectomised rats, the associated administration of estrogen and melatonin is correlated with: a less important increase in the body weight, under the conditions of unchanged food consumption, a decrease in intra-retroperitoneal fat, a decrease in total cholesterol, an increase in HDL-cholesterol levels. -
General Endocrinology
Ciortea R, Mihu D, Georgescu CE, Borda MI, Ungur RA, Irsay L, Ciortea V
Influence of the Association of Melatonin and Estrogens on Bone Turnover Markers in Ovariectomised RatsActa Endo (Buc) 2015 11(4): 425-430 doi: 10.4183/aeb.2015.425
AbstractIntroduction. Bone formation takes place through a continuous remodeling process, which involves the resorption of old bone by osteoclasts and the formation of new bone tissue by osteoblasts, melatonin contributing to the hormonal modulation of the action of osteoblasts and osteoclasts. Aim. The aim of this study is to evidence the influence of melatonin administered in combination with estrogen on bone turnover markers in female Wistar rats with bilateral surgical ovariectomy. Material and method. The study was performed on 40 female Wistar rats with a weight of 160-200 g, which underwent bilateral surgical ovariectomy. At 14 days postovariectomy, hormone replacement therapy (estradiol benzoate – E2b – 10 μg/day) and combined estrogen (estradiol benzoate – E2b – 10 μg/day) and melatonin (added to the drinking water in a concentration of 25 μg/mL or 50 μg/mL – ethanol concentration 0.01%) – treatment were initiated over a period of 12 consecutive weeks. Subsequently, venous blood was collected for the determination of serum osteocalcin and C-terminal telopeptide of collagen type I levels. Results. Melatonin administered in combination with estrogen to ovariectomized female rats induces an increase in serum osteoalcin levels (statistically significant differences between all four groups p=0.001) and a decrease in serum C-terminal telopeptide of collagen type I levels (statistically significant differences between group I and the other three groups p=0.005; p=0.001; p=0.001 and between group II and group IV p=0.007). The influence on bone formation and resorption markers depends on the administered melatonin dose and on the post-ovariectomy estradiol level. Conclusions. Melatonin potentiates the effects of estradiol on bone in ovariectomized rats.